Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus gemcitabine-based chemotherapy in unresectable biliary tract cancer (China, phase IIIb)
CTR20231590Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer, sponsored by AstraZeneca. Started Jun 2023; status: completed.
02
Drugs
durvalumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on CTR20231590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231590.